Results

1–10 of 29 results for anti-VEGF injections

Progression to Pars Plana Vitrectomy After Monotherapy With Panretinal Photocoagulation or Anti-VEGF injections in Proliferative Diabetic Retinopathy
Karen M Wai, MD
Annual Meeting Talks
2023
Intended vs Actual Intervals Between Intravitreal Anti-VEGF Injections and Assessment of Treatment Delays
Christina Y Weng, MD, MBA, FASRS
Annual Meeting Talks
2023
National vs International Outcomes and Practice Patterns of Intravitreal Anti-VEGF Injections for Retinopathy of Prematurity
Nimesh A. Patel, MD
Annual Meeting Talks
2022
The Impact of the COVID-19 Pandemic on Aflibercept and Ranibizumab Anti-VEGF Injections
Kapil Mishra, MD
On Demand Cases, Courses, and Papers
2021
PRN Cycles of Three Monthly Anti-VEGF Injections in Diabetic Macular Edema: 12- and 24-Month Results
Ahmad Rehmani, DO
On Demand Cases, Courses, and Papers
2021
Loss to Follow-up in Patients With Proliferative Diabetic Retinopathy Treated With Anti-VEGF Therapy and/or PRP in the United States
Rahul N. Khurana, MD, FASRS
Annual Meeting Talks
2021
A 10-Year Follow-up on Outcomes of Intravitreal Anti-VEGF Injections for Choroidal Neovascularization Secondary to Ocular Histoplasmosis
Carl Noble, DO, MBA
Annual Meeting Talks
2021
The Influence of Universal Face Mask Use on Endophthalmitis Risk After Intravitreal Anti-VEGF Injections During the COVID-19 Pandemic
Sunir J. Garg, MD, FACS, FASRS
Annual Meeting Talks
2021
Comparing Rates of Vitrectomy in Proliferative Diabetic Retinopathy Patients Treated With Anti-VEGF or Panretinal Photocoagulation Monotherapy
Nadim M Rayess, MD
Annual Meeting Talks
2021
Loss to Follow-up in Patients With Neovascular Age-Related Macular Degeneration Treated With Anti-VEGF Therapy in the United States
Rahul N. Khurana, MD, FASRS
Annual Meeting Talks
2020